KLRC1 and CCL5 have been shown to be involved in compromising anti-tumoral responses with KLRC1 inhibiting the killing ability of CD8+ T cells (27–32) and CCL5 recruiting immunosuppressive T regulatory cells into the tumor microenvironment (33, 34). Here, CCL5 is linked to neoplasm.